Emerging perspectives on leveraging physiologically based biopharmaceutics modeling (PBBM) for BCS class III biowaivers: A webinar summary
Bibliographic record
Abstract
The regulatory framework for Biopharmaceutics Classification System (BCS) class III drug products provides a pathway for streamlined biowaivers in drug development, eliminating the need for expensive and time-consuming bioavailability and bioequivalence studies while maintaining quality standards. To qualify, the Test must align with the excipients of the Reference product, while variations in flavor, color, and preservatives are allowed. Quantities of excipients, including changes in grade and percentage, must remain comparable, with cumulative differences not exceeding 10%. However, excipient modifications may affect drug release, potentially necessitating further evaluation for equivalence. Additionally, in cases where very rapid dissolution is not met, it limits the use of a BCS class III-based biowaiver for demonstrating bioequivalence. This article examines the regulatory landscape across regulatory agencies surrounding the application of physiologically based biopharmaceutics modeling (PBBM) to support BCS class III biowaivers, providing insights into the current level of acceptance and expectations. Additionally, it addresses the scientific and regulatory challenges associated with implementing PBBM, highlighting knowledge gaps and obstacles that could hinder adoption in regulatory decision-making. The article also presents case studies demonstrating practical approaches to leveraging PBBM and risk assessment for BCS class III biowaivers, offering valuable insights into successful applications and potential future directions.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.002 |
| Meta-epidemiology (narrow) | 0.001 | 0.000 |
| Meta-epidemiology (broad) | 0.001 | 0.001 |
| Bibliometrics | 0.000 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.004 | 0.004 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.002 | 0.002 |
| Insufficient payload (model declined to judge) | 0.021 | 0.008 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".